Fruzaqla 1 mg (Fruquintinib Capsule) 1mg

FRUZAQLA 1 MG (fruquintinib) is a prescription capsule used for managing certain types of cancer. This oral medication is designed to support treatment under medical supervision. Store below 25°C in a dry place away from light. Always follow healthcare provider instructions when using this product.

Strength

1mg

Pack Size

21s

Storage

Below 25°C

Manufacturer / TM Owner

TAKEDA PHARMACEUTICALS/ALUNBRIG

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

FRUZAQLA 1 MG (fruquintinib) is prescribed to treat adults with metastatic colorectal cancer who have received prior therapies. This capsule is part of a broader treatment plan for advanced cancer cases. It is used when standard treatments are no longer effective. Patients should discuss suitability with their oncologist before starting.

Side Effects

FRUZAQLA 1 MG (fruquintinib) capsules work by targeting specific pathways involved in cancer cell growth. Users may experience effects such as fatigue or digestive changes during treatment. Individual responses vary, and ongoing monitoring is recommended by healthcare professionals.

Precautions & Warnings

Keep FRUZAQLA 1 MG (fruquintinib) in its original packaging to protect from moisture and light. Store below 25°C and avoid exposure to high humidity. Do not use if the capsule is damaged or expired. Always handle with clean, dry hands and keep out of reach of children.

Avoid Interactions

FRUZAQLA 1 MG (fruquintinib) may interact with strong CYP3A4 inhibitors or inducers, altering its effectiveness. Grapefruit products and certain supplements can also affect how the medication works. Patients should inform their doctor about all medications and supplements being taken.

Frequently Asked Questions

FRUZAQLA 1 MG is used to treat metastatic colorectal cancer in adults after other therapies have been tried.

Store FRUZAQLA 1 MG below 25°C in a dry place, away from light and moisture.

Consult your healthcare provider before combining FRUZAQLA 1 MG with other drugs or supplements.

Common effects may include fatigue, digestive changes, or skin reactions; discuss any concerns with your doctor.

FRUZAQLA 1 MG is an oral targeted therapy, not a traditional chemotherapy agent.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.